188 related articles for article (PubMed ID: 22405968)
1. p53 and MDM2 are involved in the regulation of osteocalcin gene expression.
Chen H; Kolman K; Lanciloti N; Nerney M; Hays E; Robson C; Chandar N
Exp Cell Res; 2012 May; 318(8):867-76. PubMed ID: 22405968
[TBL] [Abstract][Full Text] [Related]
2. Bone-specific transcription factor Runx2 interacts with the 1alpha,25-dihydroxyvitamin D3 receptor to up-regulate rat osteocalcin gene expression in osteoblastic cells.
Paredes R; Arriagada G; Cruzat F; Villagra A; Olate J; Zaidi K; van Wijnen A; Lian JB; Stein GS; Stein JL; Montecino M
Mol Cell Biol; 2004 Oct; 24(20):8847-61. PubMed ID: 15456860
[TBL] [Abstract][Full Text] [Related]
3. Osteoblast differentiation and skeletal development are regulated by Mdm2-p53 signaling.
Lengner CJ; Steinman HA; Gagnon J; Smith TW; Henderson JE; Kream BE; Stein GS; Lian JB; Jones SN
J Cell Biol; 2006 Mar; 172(6):909-21. PubMed ID: 16533949
[TBL] [Abstract][Full Text] [Related]
4. Regulation of the bone-specific osteocalcin gene by p300 requires Runx2/Cbfa1 and the vitamin D3 receptor but not p300 intrinsic histone acetyltransferase activity.
Sierra J; Villagra A; Paredes R; Cruzat F; Gutierrez S; Javed A; Arriagada G; Olate J; Imschenetzky M; Van Wijnen AJ; Lian JB; Stein GS; Stein JL; Montecino M
Mol Cell Biol; 2003 May; 23(9):3339-51. PubMed ID: 12697832
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas.
Künkele A; De Preter K; Heukamp L; Thor T; Pajtler KW; Hartmann W; Mittelbronn M; Grotzer MA; Deubzer HE; Speleman F; Schramm A; Eggert A; Schulte JH
Neuro Oncol; 2012 Jul; 14(7):859-69. PubMed ID: 22591662
[TBL] [Abstract][Full Text] [Related]
6. MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin.
Hu B; Gilkes DM; Farooqi B; Sebti SM; Chen J
J Biol Chem; 2006 Nov; 281(44):33030-5. PubMed ID: 16905541
[TBL] [Abstract][Full Text] [Related]
7. Osteocalcin gene expression is regulated by wild-type p53.
Chen H; Hays E; Liboon J; Neely C; Kolman K; Chandar N
Calcif Tissue Int; 2011 Nov; 89(5):411-8. PubMed ID: 21964930
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression.
Palani CD; Beck JF; Sonnemann J
Invest New Drugs; 2012 Feb; 30(1):25-36. PubMed ID: 20680659
[TBL] [Abstract][Full Text] [Related]
9. Identification of a DNA sequence involved in osteoblast-specific gene expression via interaction with helix-loop-helix (HLH)-type transcription factors.
Tamura M; Noda M
J Cell Biol; 1994 Aug; 126(3):773-82. PubMed ID: 8045940
[TBL] [Abstract][Full Text] [Related]
10. The combination of Nutlin-3 and Tanshinone IIA promotes synergistic cytotoxicity in acute leukemic cells expressing wild-type p53 by co-regulating MDM2-P53 and the AKT/mTOR pathway.
Guo Y; Li Y; Wang FF; Xiang B; Huang XO; Ma HB; Gong YP
Int J Biochem Cell Biol; 2019 Jan; 106():8-20. PubMed ID: 30389549
[TBL] [Abstract][Full Text] [Related]
11. Protein phosphatase 1 nuclear targeting subunit is a hypoxia inducible gene: its role in post-translational modification of p53 and MDM2.
Lee SJ; Lim CJ; Min JK; Lee JK; Kim YM; Lee JY; Won MH; Kwon YG
Cell Death Differ; 2007 Jun; 14(6):1106-16. PubMed ID: 17318220
[TBL] [Abstract][Full Text] [Related]
12. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.
Saha MN; Jiang H; Jayakar J; Reece D; Branch DR; Chang H
Cancer Biol Ther; 2010 Jun; 9(11):936-44. PubMed ID: 20418664
[TBL] [Abstract][Full Text] [Related]
13. Efficient activation of p53 pathway in A549 cells exposed to L2, a novel compound targeting p53-MDM2 interaction.
Zhang L; Zhang J; Hu C; Cao J; Zhou X; Hu Y; He Q; Yang B
Anticancer Drugs; 2009 Jul; 20(6):416-24. PubMed ID: 19579266
[TBL] [Abstract][Full Text] [Related]
14. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation.
Xia M; Knezevic D; Tovar C; Huang B; Heimbrook DC; Vassilev LT
Cell Cycle; 2008 Jun; 7(11):1604-12. PubMed ID: 18520179
[TBL] [Abstract][Full Text] [Related]
15. MDM2 antagonist can inhibit tumor growth in hepatocellular carcinoma with different types of p53 in vitro.
Wang J; Zheng T; Chen X; Song X; Meng X; Bhatta N; Pan S; Jiang H; Liu L
J Gastroenterol Hepatol; 2011 Feb; 26(2):371-7. PubMed ID: 21261729
[TBL] [Abstract][Full Text] [Related]
16. Msx-2/Hox 8.1: a transcriptional regulator of the rat osteocalcin promoter.
Towler DA; Rutledge SJ; Rodan GA
Mol Endocrinol; 1994 Nov; 8(11):1484-93. PubMed ID: 7877617
[TBL] [Abstract][Full Text] [Related]
17. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
[TBL] [Abstract][Full Text] [Related]
18. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F
Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084
[TBL] [Abstract][Full Text] [Related]
19. Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).
Drakos E; Singh RR; Rassidakis GZ; Schlette E; Li J; Claret FX; Ford RJ; Vega F; Medeiros LJ
Leukemia; 2011 May; 25(5):856-67. PubMed ID: 21394100
[TBL] [Abstract][Full Text] [Related]
20. Activity of the rat osteocalcin basal promoter in osteoblastic cells is dependent upon homeodomain and CP1 binding motifs.
Towler DA; Bennett CD; Rodan GA
Mol Endocrinol; 1994 May; 8(5):614-24. PubMed ID: 7914673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]